Can Chemo Cause Colitis? Symptoms and Management

Chemotherapy can cause colitis, and it does so more often than many patients expect. The lining of the colon is made up of rapidly dividing cells, which makes it a direct target for drugs designed to kill fast-growing tissue.¹ The result can range from mild inflammation and loose stools to severe, even life-threatening bowel damage. Because “colitis” in this context can mean several different things with different causes and different urgency levels, understanding the specific type you or a loved one is dealing with matters for getting the right treatment quickly.

Why Chemotherapy Targets the Gut

Most chemotherapy drugs work by attacking cells that divide quickly. Cancer cells fit that description, but so do the cells lining your mouth, stomach, and intestines. Your colon replaces its inner lining every few days, which means it is constantly producing new cells at a rate that puts it squarely in the crosshairs of cytotoxic drugs. When chemo damages those cells faster than they can regenerate, the intestinal barrier weakens, inflammation sets in, and the colon can no longer absorb water or move waste normally. That is the basic setup for chemotherapy-induced colitis.

The damage does not happen in isolation. Once the intestinal lining is compromised, bacteria that normally stay in the gut can invade the weakened tissue and trigger an immune response on top of the chemical injury. Research has shown that disruption of the balance in gut bacteria and the compromised integrity of the intestinal barrier are key factors in the diarrhea and inflammation that follow mucositis.² So chemotherapy-induced colitis is partly a direct chemical injury and partly an inflammatory cascade fueled by the gut’s own microbial ecosystem turning against its weakened host.

Which Drugs Carry the Highest Risk

Not all chemotherapy drugs damage the colon equally. Two of the worst offenders are 5-fluorouracil (commonly called 5-FU) and irinotecan. Both are widely used in colorectal cancer treatment, which means the drugs being used to treat colon cancer can simultaneously injure the colon they are supposed to help. A meta-analysis covering tens of thousands of patients found that severe diarrhea occurred in roughly one in six patients on capecitabine (an oral form of 5-FU) and about one in eight on intravenous 5-FU regimens. When irinotecan was added to the combination, the risk of severe diarrhea more than doubled.³ The combination of 5-FU and irinotecan carries enough risk that it has been specifically flagged for potentially fatal chemotherapy-induced colitis.⁴

Taxanes, a class of drugs used for breast cancer and other solid tumors, are another significant culprit. A study of breast cancer patients on taxane-based chemotherapy found that colitis developed in a meaningful fraction of cases, sometimes requiring hospitalization.⁵ Newer targeted agents can compound the problem. Adding aflibercept to irinotecan-based chemotherapy, for example, has been shown to increase severe diarrhea, and colonoscopy with biopsies in affected patients revealed microscopic colitis even when the colon looked visually normal during the scope.⁶

That last point is worth lingering on. Microscopic colitis means the inflammation is only visible under a microscope, not during a standard colonoscopy. A doctor performing a scope may see normal-looking tissue and still miss the problem unless biopsies are taken. This is one reason severe diarrhea during chemotherapy should not be dismissed even if initial imaging looks unremarkable.

Symptoms and Timing

The symptoms of chemotherapy-induced colitis overlap heavily with ordinary side effects of chemo, which is part of what makes it tricky. Frequent watery diarrhea is the hallmark, but it can come with abdominal cramping, bloating, nausea, and in more severe cases, bloody stools or fever. In the breast cancer study mentioned above, all patients diagnosed with colitis presented with abdominal pain, and the symptoms appeared at a median of about six days into the chemotherapy cycle, with a range of three to eight days.⁵

That timing window is useful to know. Many patients are told to expect some digestive upset in the first week or so after an infusion, and mild diarrhea lasting a day or two often is just a nuisance. The red flags that distinguish routine chemo side effects from colitis include diarrhea that does not respond to over-the-counter remedies, diarrhea producing more than several episodes per day, any rectal bleeding, fever alongside abdominal symptoms, and signs of dehydration such as dizziness, dark urine, or rapid heart rate. If those features show up, it is time to call the oncology team rather than ride it out at home.

Neutropenic Enterocolitis, the Most Dangerous Form

The most serious version of chemotherapy-related colitis is neutropenic enterocolitis, sometimes called typhlitis. This condition involves inflammation and often infection of the bowel wall in patients whose white blood cell counts have cratered from chemotherapy. It occurs most commonly in people being treated for blood cancers like leukemia and lymphoma, where the chemo regimens tend to be especially intense and the resulting immune suppression is profound. Taxane drugs have also been specifically linked to rising rates of this condition in solid tumor patients.⁷

Neutropenic enterocolitis is a medical emergency. The classic presentation includes fever, abdominal pain, and diarrhea in a patient known to be neutropenic. Imaging often reveals thickening of the bowel wall, and blood cultures can come back positive for gut bacteria that have breached the damaged intestinal lining. One published case detailed a 53-year-old woman with acute myeloid leukemia who developed the condition after induction chemotherapy, with blood cultures confirming E. coli had crossed from the gut into her bloodstream.⁸ Treatment typically involves broad-spectrum antibiotics, bowel rest, and close monitoring; surgery is sometimes needed if the bowel perforates, though many cases can be managed without it.

In children, the picture is similar but the outcomes have been generally encouraging when recognized early. A review of pediatric bone marrow transplant patients found that typhlitis tended to appear about two weeks post-transplant. All affected children were managed with antibiotics and antifungal agents, none required surgery, and none died of the condition.⁹ The challenge in pediatric and adult cases alike is that early symptoms of typhlitis are hard to distinguish from ordinary abdominal pain during chemotherapy, so a high index of suspicion is needed.

Genetic Factors That Raise Your Risk

Some people are essentially wired to handle certain chemo drugs poorly. For 5-FU and its relatives, the key enzyme is dihydropyrimidine dehydrogenase, or DPD. This enzyme breaks down 5-FU in your body. If you carry certain mutations in the gene that codes for DPD, the drug accumulates to toxic levels instead of being cleared, and the gut often bears the brunt. One study of Portuguese colorectal cancer patients found a statistically significant link between mutations in the DPD gene and grade 3 or 4 toxicity from 5-FU, with a quarter of severely affected patients carrying the relevant mutations.¹⁰ DPD deficiency can be severe enough to cause life-threatening toxicity, and new variants in the gene continue to be identified.¹¹

Pre-treatment genetic testing for DPD deficiency is increasingly available and is recommended by several oncology guidelines before starting 5-FU-based chemotherapy. If testing reveals you carry one of the higher-risk variants, your oncologist can lower the dose or choose an alternative drug entirely. This is one of the more actionable pieces of information in cancer care, because the toxicity is predictable and largely preventable once you know about the genetic vulnerability.

How Chemotherapy Colitis Is Diagnosed

Diagnosing chemotherapy-induced colitis is partly about what it is and partly about ruling out what it is not. The main conditions that can look identical include Clostridioides difficile (C. diff) infection, which is common in cancer patients because of antibiotic exposure, and immune-mediated colitis from checkpoint inhibitor immunotherapy drugs. A study evaluating patients on immune checkpoint inhibitors found that C. diff infection and immune-mediated colitis can present with very similar symptoms, making clinical differentiation difficult without testing.¹²

For patients receiving traditional chemotherapy, the standard workup for new or worsening diarrhea usually includes stool tests for C. diff and other infections, blood work to check white blood cell counts and inflammatory markers, and imaging. CT scans can reveal bowel wall thickening, which is a hallmark of both chemotherapy colitis and neutropenic enterocolitis. Colonoscopy with biopsies is sometimes needed, especially when the cause is unclear or when the diarrhea is severe and not responding to initial treatment. As the aflibercept cases demonstrated, biopsy can reveal microscopic colitis that is invisible to the naked eye during the scope.⁶

Fecal calprotectin, a stool marker that reflects neutrophil migration into gut tissue, is another tool that can help. It is sensitive for intestinal inflammation and is already widely used to distinguish inflammatory bowel disease from irritable bowel syndrome. In the chemotherapy setting, elevated fecal calprotectin can help confirm that active inflammation is present, though it does not pinpoint the specific cause.¹³

Managing Chemotherapy-Induced Colitis

Treatment depends on the severity. Mild to moderate cases are usually managed with fluid replacement, dietary adjustments (low-fiber, bland foods, avoiding dairy and caffeine), and antidiarrheal medications. Loperamide is the first-line drug for most oncology patients with chemotherapy-induced diarrhea. For cases that do not respond to loperamide, octreotide is the usual step-up. A meta-analysis of randomized controlled trials found that octreotide was effective in roughly 85 to 87 percent of patients with chemotherapy- or radiation-induced diarrhea, compared with about 40 to 50 percent in control groups receiving standard care alone.¹⁴

When even octreotide is not enough, steroids become an option. One documented case involved a patient whose severe diarrhea did not respond to bismuth subsalicylate, diphenoxylate-atropine, loperamide, octreotide, or oral steroids. She was deteriorating with hypotension and dehydration before intravenous methylprednisolone was started, which rapidly reduced her symptoms. She was eventually transitioned to oral steroids and discharged on a tapering regimen.¹⁵ This is not standard first-line management, but it illustrates that options exist for truly refractory cases.

For neutropenic enterocolitis specifically, management shifts toward broad-spectrum antibiotics covering gut bacteria and fungi, intravenous fluids, bowel rest (nothing by mouth, with nutrition supplied intravenously if needed), and careful monitoring for signs of perforation. Surgical consultation is usually obtained early, though most patients are managed without an operation.

Prophylactic Approaches

Preventing colitis is obviously preferable to treating it. For patients on irinotecan, one strategy that has shown promise is prophylactic activated charcoal. In a study of patients with advanced colorectal cancer, activated charcoal given the evening before irinotecan and three times daily for 48 hours afterward reduced dose-limiting diarrhea and decreased the need for antidiarrheal medications.¹⁶ This is a simple, inexpensive intervention, though it was tested in a small, single-arm study, so it is not yet standard of care everywhere.

Other prophylactic strategies under investigation focus on the gut microbiome. Since disruption of intestinal bacteria plays a central role in chemotherapy-induced gut inflammation, researchers are exploring whether probiotics, prebiotics, or fecal microbiota approaches might protect the bowel during treatment.² Results so far are mixed, and giving live bacteria to immunocompromised patients carries its own risks, so this remains an active area of research rather than a settled recommendation. Still, many oncologists encourage patients to discuss probiotic use with their care team, especially during regimens known to be hard on the gut.

When Colitis Disrupts Cancer Treatment

One of the most practical and underappreciated consequences of chemotherapy-induced colitis is its effect on the cancer treatment itself. Severe gut toxicity is a leading reason for dose reductions, treatment delays, and outright discontinuation of chemotherapy.¹⁷ When doses are lowered or cycles are skipped to let the colon recover, the cancer may get less drug exposure than planned, which could affect how well the treatment works. This creates a difficult balancing act: the oncologist wants to give enough drug to control the cancer but not so much that the patient ends up hospitalized with colitis.

In the microscopic colitis cases linked to aflibercept plus irinotecan, all three patients had to stop treatment entirely because of their diarrhea.⁶ For patients with metastatic disease where treatment options may already be limited, losing an entire regimen to colitis is not a minor inconvenience. This is one more reason why early recognition and aggressive management of gut symptoms matter so much during chemo: the goal is not just patient comfort, but preserving the ability to continue effective cancer treatment.

Pre-Existing Inflammatory Bowel Disease

Patients who already have inflammatory bowel disease (Crohn’s disease or ulcerative colitis) face an especially complicated situation when they need chemotherapy. The concern runs in both directions. Chemotherapy can flare existing IBD, and the immunosuppressive drugs used to control IBD carry their own concerns about cancer recurrence. Clinicians managing these patients face the challenge of balancing the risk of cancer progression against the risk of worsening bowel disease.¹⁸ If you have IBD and are starting chemo, expect your oncologist and gastroenterologist to work closely together. You may need more frequent monitoring, adjusted drug choices, or proactive management of your IBD medications throughout treatment.

Chemotherapy Colitis Versus Immunotherapy Colitis

Because many cancer patients now receive both traditional chemotherapy and newer immunotherapy drugs (checkpoint inhibitors), it is worth understanding how colitis from these two sources differs. Immunotherapy colitis is driven by an overactive immune response, not by direct damage to dividing cells. It tends to be more common and more severe than chemotherapy-induced colitis. A systematic review and meta-analysis found that treatment involving checkpoint inhibitors carried roughly nine to eleven times the risk of colitis compared to chemotherapy alone, and the risk of severe colitis was even more elevated with immunotherapy monotherapy versus placebo.¹⁹

The distinction matters for treatment. Immunotherapy colitis is treated primarily with steroids and sometimes other immunosuppressants, because the mechanism is immune-mediated. Chemotherapy colitis, by contrast, often involves supportive care and antidiarrheal agents as first steps, with steroids reserved for refractory cases. If you are receiving a combination of chemotherapy and immunotherapy and develop colitis, your team needs to sort out which drug class is the likely cause, because the management approach depends on it. Stool testing for infections like C. diff is also essential, since all three causes of diarrhea in cancer patients can look identical at the bedside.¹²

What to Tell Your Oncology Team

If you are going through chemotherapy and notice a change in your bowel habits, the instinct to tough it out and wait for it to pass is understandable but potentially dangerous. A few points worth keeping in mind when deciding whether to call your care team:

Frequency matters: More than four loose or watery stools per day above your baseline is generally considered clinically significant during chemotherapy.
Blood is always urgent: Any rectal bleeding during chemo warrants a call, even if you assume it is from hemorrhoids.
Fever plus diarrhea: This combination in a patient whose white blood cell count may be low should be treated as a potential emergency. Neutropenic enterocolitis can progress quickly.
Dehydration signs: Dizziness when standing, reduced urination, dry mouth, and rapid heartbeat all suggest you are losing more fluid than you are replacing.
Failed home remedies: If loperamide is not controlling the diarrhea within 24 hours, report that. Refractory diarrhea sometimes needs hospital-level management.

Oncology teams are accustomed to these calls and would much rather hear from you early than manage a preventable hospitalization. Keeping a brief log of the number and consistency of bowel movements, along with any associated symptoms like cramping or fever, gives your team concrete data to work with when deciding next steps.

1
PubMed Central. Chemotherapy induced gastrointestinal toxicities
2
PubMed Central. Important Role of Intestinal Microbiota in Chemotherapy-induced Diarrhea and Therapeutics
3
PubMed Central. Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials
4
PubMed. Cryptotanshinone alleviates chemotherapy-induced colitis in mice with colon cancer via regulating fecal-bacteria-related lipid metabolism
5
PubMed. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy
6
PubMed. Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients
7
Clinical Infectious Diseases. Neutropenic Enterocolitis, a Growing Concern in the Era of Widespread Use of Aggressive Chemotherapy
8
Texila International Journal of Public Health. Chemotherapy-Induced Neutropenic Enterocolitis in Acute Myeloid Leukaemia Patient: A Case Report
9
PubMed. Neutropenic enterocolitis (typhlitis) after pediatric bone marrow transplant
10
Genetics in Medicine. Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients
11
PubMed. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene
12
Journal of Clinical Oncology. Clostridium difficile infection and immune mediated diarrhea and colitis in patients with cancer on immune checkpoint inhibitors
13
PubMed Central. Faecal Calprotectin
14
PubMed Central. Octreotide treatment of cancer chemoradiotherapy-induced diarrhoea: a meta-analysis of randomized controlled trials
15
PubMed Central. Intravenous Steroids for Refractory Chemotherapy-Related Diarrhea: A Case Report
16
PubMed Central. Adjunctive Treatments for the Prevention of Chemotherapy- and Radiotherapy-Induced Mucositis
17
PubMed Central. Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management
18
PubMed Central. Inflammatory Bowel Disease Treatment in Cancer Patients-A Comprehensive Review
19
PubMed Central. Risk of colitis in immune checkpoint inhibitors and in chemotherapy/placebo for solid tumors: a systematic review and meta-analysis